InsiderTrades.com logo
Breaking News: Tesla headed to $500…
From WealthPress   |   Ad
That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.
So to claim your free digital copy today, simply follow this link and enter your email address. 
Franco Valle net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Franco Valle Biography and Net Worth

SVP of Eidos Therapeutics
Presently, Franco Valle holds the position of Chief Financial & Accounting Officer for Biomea Fusion, Inc.

Mr. Valle previously occupied the position of Controller of Iovance Biotherapeutics, Inc., Senior Vice President-Finance of Graphite Bio, Inc., Principal Accounting Officer & SVP-Finance at Eidos Therapeutics, Inc. and Senior Director-Accounting at Pharmacyclics LLC.

Franco Valle received an undergraduate degree from San Jose State University.

What is Franco Valle's net worth?

The estimated net worth of Franco Valle is at least $183,315.00 as of January 12th, 2021. Mr. Valle owns 1,500 shares of Eidos Therapeutics stock worth more than $183,315 as of November 24th. This net worth approximation does not reflect any other assets that Mr. Valle may own. Learn More about Franco Valle's net worth.

How old is Franco Valle?

Mr. Valle is currently 40 years old. There are 6 older executives and no younger executives at Eidos Therapeutics. The oldest executive at Eidos Therapeutics is Dr. Uma Sinha, Chief Scientific Officer & Director, who is 64 years old. Learn More on Franco Valle's age.

How do I contact Franco Valle?

The corporate mailing address for Mr. Valle and other Eidos Therapeutics executives is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. Eidos Therapeutics can also be reached via phone at 415-887-1471 and via email at [email protected]. Learn More on Franco Valle's contact information.

Has Franco Valle been buying or selling shares of Eidos Therapeutics?

Franco Valle has not been actively trading shares of Eidos Therapeutics over the course of the past ninety days. Most recently, Franco Valle sold 1,747 shares of the business's stock in a transaction on Tuesday, January 12th. The shares were sold at an average price of $125.45, for a transaction totalling $219,161.15. Following the completion of the sale, the senior vice president now directly owns 1,500 shares of the company's stock, valued at $188,175. Learn More on Franco Valle's trading history.

Who are Eidos Therapeutics' active insiders?

Eidos Therapeutics' insider roster includes Jonathan Fox (Insider), Uma Sinha (Insider), Cameron Turtle (Insider), and Franco Valle (SVP). Learn More on Eidos Therapeutics' active insiders.

Franco Valle Insider Trading History at Eidos Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2021Sell1,747$125.45$219,161.151,500View SEC Filing Icon  
10/8/2020Sell10,643$74.97$797,905.715,444View SEC Filing Icon  
See Full Table

Franco Valle Buying and Selling Activity at Eidos Therapeutics

This chart shows Franco Valle's buying and selling at Eidos Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eidos Therapeutics Company Overview

Eidos Therapeutics logo
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Read More

Today's Range

Now: $122.21
Low: $122.21
High: $122.21

50 Day Range

MA: $123.21
Low: $120.98
High: $128.51

2 Week Range

Now: $122.21
Low: $28.39
High: $132.54

Volume

N/A

Average Volume

128,113 shs

Market Capitalization

$4.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Breaking News: Tesla headed to $500…
From WealthPress   |   Ad
That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.
So to claim your free digital copy today, simply follow this link and enter your email address.